| Neuroprotective effects of phytocannabinoid‐based medicines in experimental models of Huntington's disease O Sagredo, MR Pazos, V Satta, JA Ramos, RG Pertwee, ... Journal of neuroscience research 89 (9), 1509-1518, 2011 | 130 | 2011 |
| Sativex-like combination of phytocannabinoids is neuroprotective in malonate-lesioned rats, an inflammatory model of Huntington’s disease: role of CB1 and CB2 receptors S Valdeolivas, V Satta, RG Pertwee, J Fernández-Ruiz, O Sagredo ACS chemical neuroscience 3 (5), 400-406, 2012 | 122 | 2012 |
| Brain activity of anandamide: a rewarding bliss? M Scherma, P Masia, V Satta, W Fratta, P Fadda, G Tanda Acta Pharmacologica Sinica 40 (3), 309-323, 2019 | 114 | 2019 |
| Adolescent Δ9-tetrahydrocannabinol exposure alters WIN55, 212-2 self-administration in adult rats M Scherma, C Dessì, AL Muntoni, S Lecca, V Satta, A Luchicchi, M Pistis, ... Neuropsychopharmacology 41 (5), 1416-1426, 2016 | 75 | 2016 |
| Cannabinoid CB1/CB2 receptor agonists attenuate hyperactivity and body weight loss in a rat model of activity‐based anorexia M Scherma, V Satta, R Collu, MF Boi, P Usai, W Fratta, P Fadda British journal of pharmacology 174 (16), 2682-2695, 2017 | 49 | 2017 |
| Pharmacological modulation of the endocannabinoid signalling alters binge‐type eating behaviour in female rats M Scherma, L Fattore, V Satta, F Businco, B Pigliacampo, SR Goldberg, ... British journal of pharmacology 169 (4), 820-833, 2013 | 35 | 2013 |
| Limited access to a high fat diet alters endocannabinoid tone in female rats V Satta, M Scherma, F Piscitelli, P Usai, MP Castelli, T Bisogno, W Fratta, ... Frontiers in neuroscience 12, 40, 2018 | 30 | 2018 |
| Modeling Parkinson’s disease neuropathology and symptoms by intranigral inoculation of preformed human α-synuclein oligomers L Boi, A Pisanu, MF Palmas, G Fusco, E Carboni, MA Casu, V Satta, ... International journal of molecular sciences 21 (22), 8535, 2020 | 27 | 2020 |
| Impaired brain endocannabinoid tone in the activity‐based model of anorexia nervosa R Collu, M Scherma, F Piscitelli, E Giunti, V Satta, MP Castelli, R Verde, ... International Journal of Eating Disorders 52 (11), 1251-1262, 2019 | 26 | 2019 |
| Cannabinoid signalling in the immature brain: Encephalopathies and neurodevelopmental disorders O Sagredo, J Palazuelos, A Gutierrez-Rodriguez, V Satta, I Galve-Roperh, ... Biochemical Pharmacology 157, 85-96, 2018 | 26 | 2018 |
| Neuropathological characterization of a Dravet syndrome knock-in mouse model useful for investigating cannabinoid treatments V Satta, C Alonso, P Díez, S Martín-Suárez, M Rubio, JM Encinas, ... Frontiers in Molecular Neuroscience 13, 602801, 2021 | 23 | 2021 |
| Emotional profile of female rats showing binge eating behavior V Satta, M Scherma, E Giunti, R Collu, L Fattore, W Fratta, P Fadda Physiology & Behavior 163, 136-143, 2016 | 22 | 2016 |
| Analysis of endocannabinoid signaling elements and related proteins in lymphocytes of patients with Dravet syndrome M Rubio, S Valdeolivas, F Piscitelli, R Verde, V Satta, E Barroso, ... Pharmacology research & perspectives 4 (2), e00220, 2016 | 18 | 2016 |
| Animal models of eating disorders M Scherma, R Collu, V Satta, E Giunti, P Fadda Psychiatric Disorders, 297-314, 2019 | 11 | 2019 |
| Novel sulfenamides and sulfonamides based on pyridazinone and pyridazine scaffolds as CB1 receptor ligand antagonists G Murineddu, F Deligia, G Ragusa, L García-Toscano, M Gómez-Cañas, ... Bioorganic & medicinal chemistry 26 (1), 295-307, 2018 | 10 | 2018 |
| Preclinical investigation of β-caryophyllene as a therapeutic agent in an experimental murine model of Dravet syndrome C Alonso, V Satta, P Díez-Gutiérrez, J Fernández-Ruiz, O Sagredo Neuropharmacology 205, 108914, 2022 | 9 | 2022 |
| Characterisation of a Dravet syndrome knock-in mouse model useful for investigating cannabinoid-based treatments CA Gómez, V Satta, J Fernández-Ruiz, O Sagredo European Neuropsychopharmacology 28, S41, 2018 | 5 | 2018 |
| The endocannabinoid system: Anorexia nervosa and binge eating disorder M Scherma, V Satta, W Fratta, P Fadda Cannabinoids in neurologic and mental disease, 389-413, 2015 | 5 | 2015 |
| Possible dysregulation of the endocannabinoid system in a cohort of patients with Dravet syndrome V Satta, M Rubio, S Valdeolivas, F Piscitelli, R Verde, E Barroso, ... Eur Neuropsychopharmacol 26, S251, 2016 | 1 | 2016 |
| Preclinical investigation of β-caryophyllene as a therapeutic agent in an experimental murine model of Dravet syndrome C Alonso Gómez, V Satta, P Díez Gutiérrez, J Fernández Ruiz, ... Elsevier, 2022 | | 2022 |
